Free Trial

Alliance Pharma (APH) Stock Forecast & Price Target

Alliance Pharma logo
GBX 46 +0.30 (+0.66%)
(As of 07:50 AM ET)

Alliance Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for Alliance Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for APH.

Consensus Price Target

GBX 60
According to the 1 analysts' twelve-month price targets for Alliance Pharma, the average price target is GBX 60. The highest price target for APH is GBX 60, while the lowest price target for APH is GBX 60. The average price target represents a forecasted upside of 30.43% from the current price of GBX 46.
Get the Latest News and Ratings for APH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alliance Pharma and its competitors.

Sign Up

APH Analyst Ratings Over Time

TypeCurrent Forecast
12/25/23 to 12/24/24
1 Month Ago
11/25/23 to 11/24/24
3 Months Ago
9/26/23 to 9/25/24
1 Year Ago
12/25/22 to 12/25/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 60GBX 60GBX 56.50GBX 87.67
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

APH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

APH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alliance Pharma Stock vs. The Competition

TypeAlliance PharmaMedical Companies
Consensus Rating Score
3.00
2.81
Consensus RatingBuyModerate Buy
News Sentiment Rating
Positive News

See Recent APH News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/31/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperformGBX 65 ➝ GBX 60+59.79%
9/26/2023Peel Hunt
3 of 5 stars
 Reiterated RatingHoldGBX 53+9.73%
5/25/2023Numis Securities
1 of 5 stars
 Reiterated RatingBuyGBX 105+70.45%
5/25/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 105+70.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:35 PM ET.


APH Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Alliance Pharma is GBX 60, with a high forecast of GBX 60 and a low forecast of GBX 60.

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alliance Pharma in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APH shares.

According to analysts, Alliance Pharma's stock has a predicted upside of 30.43% based on their 12-month stock forecasts.

Analysts like Alliance Pharma more than other "medical" companies. The consensus rating for Alliance Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how APH compares to other companies.


This page (LON:APH) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners